Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5192208 | 0.81 | P2RY6 (0.33) | PDE4DPDE3ASLC29A1POLBLMNA | |
| SCHEMBL6884819 | 0.79 | POLB (0.37) | POLBLMNATHRBMTORMDM2 | |
| SCHEMBL8098949 | 0.77 | SLC28A1 (0.43) | SLC29A1P2RY6 | |
| SCHEMBL30712249 | 0.72 | PDE3A (0.45) | PDE4DPDE3ASLC29A1POLBLMNA | |
| SCHEMBL5190899 | 0.72 | PDE4D (0.37) | PDE4DPDE3ASLC29A1POLBLMNA | |
| SCHEMBL29891526 | 0.72 | LMNA (0.36) | PDE4DPDE3ASLC29A1POLBLMNA | |
| SCHEMBL23648127 | 0.72 | PDE3A (0.44) | PDE4DPDE3ASLC29A1POLBLMNA | |
| SCHEMBL30358186 | 0.72 | PDE3A (0.44) | PDE4DPDE3ASLC29A1POLBLMNA | |
| SCHEMBL29891333 | 0.70 | LMNA (0.34) | PDE4DPDE3ASLC29A1POLBLMNA | |
| SCHEMBL8903799 | 0.68 | TK1 (0.42) | POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | PDE4D 701/4885PDE3A 763/4885SLC29A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.